Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 02:18:37 2024-09-18 pm EDT 		5-day change 1st Jan Change
26.26 USD +1.02% Intraday chart for Dianthus Therapeutics, Inc. -6.51% +149.90%
Aug. 09 Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating MT
Aug. 08 Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI

Press Releases

Search
See the results
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
100% Free Registration
Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September
AQ
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
AQ
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
AQ
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
AQ
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
AQ
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
AQ
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
AQ
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. News Dianthus Therapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW